Profiles

1.	Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, Walker BD. Vigorous HIV-1-specific CD4+T cell responses associated with control of viremia. Science. 1997; 278:1447-50.
2.	Rosenberg ES, Cotton D. Primary HIV infection and the acute retroviral syndrome: The urgent need for recognition. AIDS Clinical Care. 1997; 9(3):19,23-5.
3.	Hay C, Rosenberg ES. Immunologic response to HIV. AIDS Clinical Care. 1998; 10(1):1-3.
4.	Rosenberg ES, Walker BD. HIV type 1-specific helper T cells: A critical host defense. AIDS Research and Human Retroviruses. 1998; 14:143-7.
5.	Walker BD, Rosenberg ES, Hay CM, Basgov N, Yang OO. Immune control of HIV-1 replication. Adv Exp Med Biol. 1998; 452:159-67.
6.	Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B,Gange S, Gallant J, Siliciano RF. Latent infection of CD4+T cells provides a mechanism for lifelong persustence of HIV-1, even in patients on effective combination therapy. Nature. 1999; 5:512-7.
7.	Kalams SA, Buchbinder SP, Rosenberg ES, Billingsley JM, Colbert DS, Jones NG, Shea AK, Trocha AK, Walker BD. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection. Journal of Virology. 1999; 73:6715-20.
8.	Lisziewiez J, Rosenberg E, Lieberman J, Jessen H, Lopalco L, Siliciano R, Walker B, Lori F. Control of HIV despite the discontinuation of antiretroviral therapy. New England Journal of Medicine. 1999; 340:168304.
9.	Little SJ, Daar ES, D'Aquila RT, Keiser PH, Connick E, Whitcomb JM, Hellmann NS, Petropoulos CJ, Sutton L, Pitt JA, Rosenberg ES, Koup RA, Walker BD, Richman DD. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. Journal of the American Medical Association. 1999; 282:1142-9.
10.	Lori F, Jessen H, Lieberman J, Finzi D, Rosenberg E, Tinelli C, Walker B, Siliciano RF, Lisziewicz J. Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before serovoncersion is associated with normalized immune parameters and limited viral reservoir. Journal of Infectious Diseases. 1999; 180:1827-32.
11.	Lori F, Rosenberg E, Lieberman J, Foli A, Maserati R, Seminari E, Alberici F, Walker B, Lisziewicz J. Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters. AIDS Research and Human Retroviruses. 1999; 15:1333-8.
12.	Rosenberg ES, Caliendo AM, Walker BD. Acute HIV infection among patients tested for mononucleosis. New England Journal of Medicine. 1999; 340:969.
13.	Rosenberg ES, LaRosa L, Robbins G, Walker BD. Characterization of HIV-1 specific T-helper cells in acute and chronic infection. Immunology Letters. 1999; 66:89-93.
14.	Altfeld M, Rosenberg ES. The role of CD4(+) T helper cells in the cytotoxic T lumphocyte response to HIV-1. Current Opinions in Immunology. 2000; 12:375-80.
15.	Altfeld MA, Trocha A, Eldridge RL, Rosenberg ES, Phillips MN, Addo MM, Sekaly RP, Kalams SA, Burchett SA, McIntoch K, Walker BD, Goulder PJR . Identification of dominant optimal HLA-B60- and B61-restricted CTL epitopes: Rapid characterization of CTL responses by ELISPOT assay. Journal of Virology. 2000; 74:8541-9.
16.	Cosimi L, Rosenberg ES. The characterization of HIV-1 specific CD4+T helper epitopes. HIV Molecular Immunology Database. 2000.
17.	Goulder PJ, Brander C, Annamalai K, Mngqundaniso N, Govender U, Tang Y, He S, Hartman KE, O'Callaghan CA, Ogg GS, Altfeld MA, Rosenberg ES, Cao H, Kalams SA, Hammond M. Bunce M. Pelton SI, Burchett SA, McIntoch K, Coovadia HM, Walker BD. Differential narrow focusing of immunodominant human immunodeficiency virus gag-specific cytotoxic T-lymphocyte responses in infected African and caucasoid adults and children. Journal of Virology. 2000; 74:5679-90.
18.	Martinez-Picardo J, DePasquale MP, Kartsonis N, Hanna GJ, Wong J, Finzi D, Rosenberg ES, Gunthard HF, Sutton L, Savara A, Petropoulos C, Hellmann N, Walker BD, Richman DD, D'Aquila RT. Antiretroviral resistance during successful therapy of human immunodeficiency virus type 1 infection. Proceedings of the National Adacemy of Sciences USA. 2000; 97:10948-53.
19.	Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Walkes B, Eldridge RL, Robbins GK, D'Aquila RD, Goulder PJR, Walker BD. Immune control of HIV-1 following early treatment of acute infection. Nature. 2000; 407:523-526.
20.	Rosenberg, ES, Rubin RH. Infections in renal transplant recipients. Management of Infections in Immunocompromised Patients. 2000; 267-294.
21.	Rubin RH, Rosenberg ES. Infection in solid organ transplantation: An introduction. Management of infections in immunocompromised patients. 2000; 247-266.
22.	Tremblay CL, Giguel F, Merrill DP, Wong JT, Rosenberg E, Kalams S, Walker BD, D'Aquila RT, Hirsch MS. Marked differences in quantity of infectous human immunodeficiency virus type 1 detected in persons with controlled plasma viremia by a simple enhanced culture method. Journal of Clinical Microbiology. 2000; 38:4246-4248.
23.	Walker BD, Rosenberg ES. Containing HIV after infection. Nature Medicine. 2000; 6(10):1094-5.
24.	Hay CM, Rosenberg ES. Immunology of HIV-1 infection. Up-To-Date Online. 2000.
25.	Addo MM, Altfeld M, Rosenberg ES, Eldridge RL, Phillips MN, Habeeb K, Khatri A, Brander C. Robbins GK, Mazzara GP, Goulder PJR, Walker BD. The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T-lymphocytes (CTL) derived from HIV-1 infected individuals. Proceedings of the National Academy of Sciences USA. 2001; 98:1781-1786.
26.	Altfeld M, Rosenberg ES, Shankarappa R, Mukherjee JS, Hecht Fm Eldridge RL, Addo MM, Poon SH, Phillips MN, Robbins GK, Kahn JO, Brander C, Goulder PJ, Levy JA, Mullins JI, Walker BD. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. Journal of Experimental Medicine. 2001; 193:169-180.
27.	Altfeld MA, Livingston B, Reshamwala N, Nguyen PT, Addo M, Shea A,Newman M, Fikes J, Sidney J, Wentwoeth P, Chesnut R, Eldridge RL, Rosenberg ES, Robbins GK, Sax PE, Poswell S. Flynn T, Buchhbinder Sm, Goulder PJ, Walker BD, Sette A, Kalams SA. Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lumphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motif. Journal of Virology. 2001; 75:1301-1311.
28.	Day CL, Shea AK, Altfeld MA, Olson DP, Buchbinder SP, Hecht FM, Rosenberg ES, Walker BD, Kalams SA. Relative dominance of epitope-specific cytotoxic T lymphocyte responses in human immunodeficiency virus type 1-infected persons with shared HLA alleles. Journal of Virology. 2001; 75:6279-91.
29.	Flores-Villanueva PO, Yunis EJ, Delgato JC, Vittinghoff E, Buchbinder S, Leung JY, Uglialoro AM, Clavijo OP, Rosenberg ES, Kalams SA, Braun JD, Boswell SL, Walker BD, Goldfeld AE . Control of HIV-1 viremia and protection from AIDS are associated with HLA-Bw4 homozygosity. Proceedings of the National Academy of Sciences USA. 2001; 98:5140-5145.
30.	Goulder PJR, Addo MM, Altfeld M, Rosenberg ES, Tang Y, Govender U, Mngqundaniso N, Annamalai K, Hammond M, Bunce M, Coovadia HM, Walker BD. Rapid definition of 5 novel HLA-A*3002-restricted HIV-specific CTL epitopes by Elispot and intracellular cytokine staining assays. Journal of Virology. 2001; 75:1339-1347.
31.	Goulder PJR, Altfeld M, Rosenberg ES, Nguyen T, Tang Y, Eldridge R, Addo MM, He S, Mukherjee J, Phillips MN, Bunce M,Kalams SA, Sekaly RP, Walker BD, Brander C. Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. Journal of Experimental Medicine. 2001; 193(181-194).
32.	Goulder PJR, Brander C, Tang Y, Tremblay C. Colbert RA, Addo MA, Rosenberg ES, Nguyen T, Allen R. Trocha A, Altfeld M, He S, Buncell M, Funkhouser R, Pelton S, Burchett SK, McIntock K, Korber BTM, Walker BD. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature. 2001; 412:334-338.
33.	Goulder PJR, Tang Y, Brander C, Betts M, Altfeld M, Annamalai K, Trocha A, He S, Rosenberg ES, Ogg G, O'Callahan CA, Kalams SA, McKiney RE, Mayer K, Joup RA, Pelton SI, Burchett SK, McIntosh K, Walker BD. Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children. Journal of Experimental Medicine. 2001; 192:1819-32.
34.	Hurtado R, Rosenberg ES. Before seroconversion: The clinical and scientific events of acute HIV-1 infection and the immunologic benefits of treatment. AIDS Clinical Care. 2001.
35.	Montefiori DC, Hill TS, Vo HTT, Walker BD, Rosenberg ES. Neutralizing antibodies associated with viremia control in a subset of individuals following treatment of acute human immunodeficiency virus type 1 infection. Journal of Virology. 2001; 75:10200-7.
36.	Norris PJ, Rosenberg ES. Cellular immune response to human immunodeficiency virus. AIDS. 2001; 15:16-21.
37.	Norris PJ, Sumaroka M. Brander C, Moffett HF, Boswell SL, Nguyen T, Sykulev Y, Walker BD, Rosenberg ES,. Multiple effector functions mediated by HIV-1-specific CD4+T cell clones. Journal of Virology. 2001; 75:9771-9779.
38.	Walensky RP, Rosenberg ES, Ferraro MJ, Losina E, Walker BD, Freedberg KA. Investigation of primary human immunodeficiency virus infection in patients who test positive for heterophile antibody. Clinical Infectious Diseases. 2001; 33:570-572.
39.	Addo MM, Altefeld M, Rathod A, Yu M, Yu XG, Goulder PG, Rosenberg ES, Walker BD. HIV-1 Vpu represents a minor target for cytotoxic T lumphocytes in HIV-1 infection. AIDS. 2002; 16:1071-3.
40.	Addo MM, Yu XG, Rosenberg ES, Walker BD, Altfeld M. Cytotoxic T-lymphocyte (CTL) responses directed against regulatory and accessory proteins in HIV-1 infection. DNA Cell Biology. 2002; 21:671-8.
41.	Addo, MM, Rosenberg ES. Cellular immune responses in transplantation-associated chronic viral infections. Transplant Infectious Disease. 2002; 4(1):31-40.
42.	Altfeld M, Allen TM, Yu XG, Johnston MN, Agrawal D, Korber BT, Montefiori DC, O'Connor DH, David B, Lee PK, Harlow J, Brander C, Rosenberg ES, Walker BD. HIV-1 superinfection despite broadly directed CD8+T cell responses containing replication of the primary virus. Nature. 2002; 420:434-9.
43.	Cameron T, Norris P, Patel; A, Moulon C, Rosenberg ES, Mellins E, Wedderburn L, Stern L. Labeling antigen=-specific CD4(+)T cells with class II MHC oligomers. Journal of Immunological Methods. 2002; 268(1):51.
44.	Cohen GB, Islam SA,Noble MS, Lau C, Brander C. Altfeld M. Rosenberg ES, Schmitz JE, Cameron TO, Kalams SA. Clonotype Tracking of TCR Repertoires during Chronic Cirus Infections. Virology. 2002; 304(2):474-84.
45.	Norris PJ, Rosenberg ES. CD4(+)T helper cells and the role they play in viral control. Journal of Molecular Medicine. 2002; 80(7):397-405.
46.	Rosenberg E. Backgrounder: recognizing and diagnosing primary HIV infection. Res Initiat Treat Action. 2002; 7(2):5-10.
47.	Yu XG, Addo MM, Rosenberg ES, Rodriguez WR, Lee PK, Fitzpatrick CA, Johnston MN, Strict D, Goulder PJ, Walker BD, Altfeld M. Consistent patterns in the development and immunodominance of human immunodeficiency virus type 1 (HIV-1)-specific CD8+T-cell responses following acute HIV-1 infection. Journal of Virology. 2002; 17:8690-8701.
48.	Yu XG, Shang H, Addo MM, Eldridge RL, Phillips MN, Feeney ME, Strick D, Brander C, Goulder PJ, Rosenberg ES, Walker BD, Altfeld M. Important contribution of p15 Gag-specific responses to the total Gag-specific CTL responses. AIDS. 2002 Feb 15; 16(3):321-8.
49.	Lauer GM, Nguyen TN, Day CL, Robbins GK, Flynn T, McGowan K, Rosenberg ES, Lucas M, Klenerman P, Chung RT, Walker BD. Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses. J Virol. 2002 Mar; 76(6):2817-26.
50.	Norris PJ, Rosenberg ES. CD4(+) T helper cells and the role they play in viral control. J Mol Med. 2002 Jul; 80(7):397-405.
51.	Addo MM, Altfeld M, Rathod A, Yu M, Yu XG, Goulder PJ, Rosenberg ES, Walker BD. HIV-1 Vpu represents a minor target for cytotoxic T lymphocytes in HIV-1-infection. AIDS. 2002 May 3; 16(7):1071-3.
52.	Hecht FM, Busch MP, Rawal B, Webb M, Rosenberg E, Swanson M, Chesney M, Anderson J, Levy J, Kahn JO. Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS. 2002 May 24; 16(8):1119-29.
53.	Lotti B, Wendland T, Furrer H, Yawalkar N, von Greyerz S, Schnyder K, Brandes M, Vernazza P, Wagner R, Nguyen T, Rosenberg E, Pichler WJ, Brander C. Cytotoxic HIV-1 p55gag-specific CD4+ T cells produce HIV-inhibitory cytokines and chemokines. J Clin Immunol. 2002 Sep; 22(5):253-62.
54.	Yu XG, Addo MM, Rosenberg ES, Rodriguez WR, Lee PK, Fitzpatrick CA, Johnston MN, Strick D, Goulder PJ, Walker BD, Altfeld M. Consistent patterns in the development and immunodominance of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses following acute HIV-1 infection. J Virol. 2002 Sep; 76(17):8690-701.
55.	Cameron TO, Norris PJ, Patel A, Moulon C, Rosenberg ES, Mellins ED, Wedderburn LR, Stern LJ. Labeling antigen-specific CD4(+) T cells with class II MHC oligomers. J Immunol Methods. 2002 Oct 1; 268(1):51-69.
56.	Altfeld M, Allen TM, Yu XG, Johnston MN, Agrawal D, Korber BT, Montefiori DC, O'Connor DH, Davis BT, Lee PK, Maier EL, Harlow J, Goulder PJ, Brander C, Rosenberg ES, Walker BD. HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature. 2002 Nov 28; 420(6914):434-9.
57.	Cohen GB, Islam SA, Noble MS, Lau C, Brander C, Altfeld MA, Rosenberg ES, Schmitz JE, Cameron TO, Kalams SA. Clonotype tracking of TCR repertoires during chronic virus infections. Virology. 2002 Dec 20; 304(2):474-84.
58.	Addo MM, Yu XG, Rathod A, Cohen D, Eldridge RL, Strick D, Johnston MNm, Corcoran C, Wurcel AG, Fitzpatrick CA, Feeney ME, Rodriguez WR, Basgov N, Draenert R, Stone DR, Brander C, Goulder PJ, Rosenberg ES, Altfeld M, Walker BD. Comprehensive epitome analysis of human immunodeficiency virus type 1 (HIV-2)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. Journal of Virology. 2003; 77:2081-92.
59.	Altfeld M, Addo MM, Shankarappa R, Lee PK, Allen TM, Yu XG, Rathod A, Harlow J, O'Sullivan K, Johnston MN, Goulder PJ, Mullins JI, Rosenberg ES, Brander C, Korber B, Walker BD. Enhanced detection of human immunodeficiency virus type 1-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences. Journal of Virology. 2003; 77(7330-40).
60.	Choe H, Li W, Wright PL, Vasilieva N, Venturi M, Huant CC, Grundner C, Dorfman T, Zwick MB, Wang L, Rosenberg ES, Kwong PD, Burton DR, Robinson JE, Sodroski JG, Farzan M. Tyrosine sulfation of human antibodies contributes to recognition of the CCR4 binding region of HIV-1 gp120. Cell. 2003; 114:161-70.
61.	Gandhi RT, Wurcel A, Rosenberg, ES, Johnston MN, Hellman N, Bates M, Hirsch MS, Walker BD. Progressive reversion of human immunodeficiency virus Type 1 resistance mutations in vivo after transmission of multiply drug-resistant virus. Clinical Infectious Diseases. 2003; 37:1693-98.
62.	Kaufmann DE, Rosenberg ES. The value of preserving HIV-specific immune responses. Journal of HIV Therapy. 2003; 8:19-25.
63.	Montefiori DC, Altfeld M, Lee PK, Bilska M, Johnston MN, Gao F, Walker BD, Rosenberg ES. Viremia control despite escape from rapid and potent neutralizing antibody response after treatment-interruption in an HIV-1 infected individual. Journal of Immunology. 2003; 170:3906-14.
64.	Robbins GK, Addo MM, Troung H, Rathod A, Habeeb K, Davis B, Heller H, Basgov B, Walker BD, Rosenberg ES. Augmentation of HIV-1 specific T helper cell responses in chronic HIV-1 infection by therapeutic immunization. AIDS. 2003; 17:1121-26.
65.	Rosenberg ES. Therapeutic vaccination: Where are we now?. AIDS Clinical Care. 2003; 15:1-3.
66.	Thorner A, Rosenberg E. Early versus delayed antiretroviral therapy in patients with HIV infection : a review of the current guidelines from an immunological perspective. Drugs. 2003; 63(13):1325-37.
67.	Thorner A, Rosenberg ES. Early versus delayed antiretroviral therapy in patients with HIV infection: A review of the current buidelines from an immunological perspective. Drugs. 2003; 63:1325-37.
68.	Tong Q, Sankale J, Hadigan C, Tan G, Rosenberg ES, Kanki P, Grinspoon S, Hotamisligil G. Regulation of Adiponectin in HIV-Infected patients: Relationship to body composition and metabolic indices. The Journal of Clinical Endocrinology and Metabolism. 2003; 88:1559-64.
69.	Tremblay CL, Hicks JL, Sutton L, Giguel F, Flynn T, Johnston M, Sax PE, Walker BD, Hirsch MS, Rosenberg ES, D'Aquila RT. Antiretroviral resistance associated with supervised treatment interruptions in treated acute infection. AIDS. 2003; 17:1086-9.
70.	Kaufmann DE, Rosenberg ES. The value of preserving HIV-specific immune responses. J HIV Ther. 2003 Feb; 8(1):19-25.
71.	Montefiori DC, Altfeld M, Lee PK, Bilska M, Zhou J, Johnston MN, Gao F, Walker BD, Rosenberg ES. Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1-infected individual. J Immunol. 2003 Apr 1; 170(7):3906-14.
72.	Tong Q, Sankalé JL, Hadigan CM, Tan G, Rosenberg ES, Kanki PJ, Grinspoon SK, Hotamisligil GS. Regulation of adiponectin in human immunodeficiency virus-infected patients: relationship to body composition and metabolic indices. J Clin Endocrinol Metab. 2003 Apr; 88(4):1559-64.
73.	Tremblay CL, Hicks JL, Sutton L, Giguel F, Flynn T, Johnston M, Sax PE, Walker BD, Hirsch MS, Rosenberg ES, D'Aquila RT. Antiretroviral resistance associated with supervised treatment interruptions in treated acute HIV infection. AIDS. 2003 May 2; 17(7):1086-9.
74.	Robbins GK, Addo MM, Troung H, Rathod A, Habeeb K, Davis B, Heller H, Basgoz N, Walker BD, Rosenberg ES. Augmentation of HIV-1-specific T helper cell responses in chronic HIV-1 infection by therapeutic immunization. AIDS. 2003 May 23; 17(8):1121-6.
75.	Altfeld M, Addo MM, Shankarappa R, Lee PK, Allen TM, Yu XG, Rathod A, Harlow J, O'Sullivan K, Johnston MN, Goulder PJ, Mullins JI, Rosenberg ES, Brander C, Korber B, Walker BD. Enhanced detection of human immunodeficiency virus type 1-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences. J Virol. 2003 Jul; 77(13):7330-40.
76.	Choe H, Li W, Wright PL, Vasilieva N, Venturi M, Huang CC, Grundner C, Dorfman T, Zwick MB, Wang L, Rosenberg ES, Kwong PD, Burton DR, Robinson JE, Sodroski JG, Farzan M. Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. Cell. 2003 Jul 25; 114(2):161-70.
77.	Xiang SH, Wang L, Abreu M, Huang CC, Kwong PD, Rosenberg E, Robinson JE, Sodroski J. Epitope mapping and characterization of a novel CD4-induced human monoclonal antibody capable of neutralizing primary HIV-1 strains. Virology. 2003 Oct 10; 315(1):124-34.
78.	Gandhi RT, Wurcel A, Rosenberg ES, Johnston MN, Hellmann N, Bates M, Hirsch MS, Walker BD. Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus. Clin Infect Dis. 2003 Dec 15; 37(12):1693-8.
79.	Altfeld M, Addo MM, Rosenberg ES, Hecht FM, Lee PK, Vogel M, Yu XG, Draenert R, Johnston MN, Strick D, Allen TM, Feeney ME, Kahn JO, Sekaly RP, Levy JA, Rockstroh JK, Goulder PJ, Walker BD. Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. AIDS. 2003 Dec 5; 17(18):2581-91.
80.	Ali T, Scott N, Kallas W, Halliwell ME, Savino C, Rosenberg ES, Ferraro MJ, Hohmann E. Detection of influenza antigen using antibody-based tests after administration of live intranasal influenza vaccine (FluMist™). Clinical Infectious Diseases. 2004; 38:760-62.
81.	Allen TM, Altfeld M, Yu XG, O'Sullivan KM, Lichterfeld M, Le Gall S, John M, Mothe BR, Lee PK, Kalife ET, Cohen DE, Freedberg KA, Strick DA, Johnston MN, Sette A, Rosenberg ES, Mallal SA, Goulder PJR, Brander C, Walker BD. Selection, transmission and reversion f an antigen processing CTL escape mutation in HIV-1 infection. Journal of Virology. 2004; 78:7069-78.
82.	Chien PC, Chen D, Chen P, Tuen M, Cohen S, Migueles SA, Connors M, Rosenberg ES, Malhotra U, Gonzalez C, Hioel CE. Human immunodeficiency virus Type 1-infected patients with envelope-specific lymphoproliferation and long-term nonprogressors lack antibodies suppressing gp120 antigen presentation. Journal of Infectious Diseases. 2004; 189:852-861.
83.	Hess C, Altfeld M, Thomas SY, Addo MM, Rosenberg ES, Allen TM, Draenert R, Eldridge RL, van Lunzan J, Stellbrink HJ, Walker BM, Luster AD. HIV-1 specific CD8+ T cells with an effector phenotype and control of viral replication. Lancet. 2004; 363:863-6.
84.	Kassutto S, Rosenberg ES. Primary HIV-1 infection. Clinical Infectious Diseases. 2004; 38:1447-53.
85.	Kassutto S, Rosenberg ES. Rapid HIV-1 testing. Point of Care. 2004; 3:123-129.
86.	Kaufman DE, Bailey PM, Sidney J, Wagner B, Norris PJ, Johnston MN, Cosimi LA, Addo MM, Lichtenfeld M, Altfeld M, Frahm N, Brander C, Sette A, Walker BD, Rosenberg ES. Comprehensive analysis of HIV-1 specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides. Journal of Virology. 2004; 78:4463-77.
87.	Kaufmann DE, Lichterfeld M, Altfeld M, Addo MM, Johnston MN, Lee PK, Wagner BS, Kalifer E, Strick D, Rosenberg ES, Walker BD. Limited durability of viral control following treated acute HIV infection. Plos Med. 2004; 2(2):36.
88.	Lichterfeld M, Kaufmann DE, Yu XG, Mui SK, Addo MM, Johnston M, Cohen D, Robbins, GK, Pae E, Alter G, Wurcel A, Stone D, Rosenberg ES, Walker BD, ltfeld M, . Loss of HIV-1-specific CD8+T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1 specific CD4+T cells. Journal of Experimental Medicine. 2004; 200:701-12.
89.	Lichterfeld M, Yu XG, Waring MT, Mui SK, Johnston M, Cohen D, Addo MM, Zaunders J, Alter G, Pae E, Strick D, Allen TM, Rosenberg ES, Walker BD, Altfeld M. HIV-1 specific cytotoxicity is preferentially mediated by a subset of CD8+ T cells producing both interferon-(gamma) and tumor-negrosis factor-(alpha). Blood. 2004; 104:487-97.
90.	Norris PJ, Moffett HF, Brander C, Allen TM, Cosimi LA, Kaufmann DE, Walker BD, Rosenberg ES. Fine specificity and cross-clade reactivity of HIV-1 Gag-specific CD4+T cells. AIDS Research and Human Retroviruses. 2004; 20:315-25.
91.	Norris PJ, Moffett HF, Yang OO, Kaufmann DE, Addo MM, Rosenberg ES. Beyond Help: Direct effector functions of HIV-1-specific CD4+T cells. Journal of Virology. 2004; 78:8844-51.
92.	Quayle AJ, Fidel P, Rosenberg ES. Sex, alloimmunisation and susceptibility to HIV infection. Lancet. 2004; 363:503-4.
93.	Rodriguez WR, Addo MM, Rathod A, Fitzpatrick CA, Yu XG, Perkins BA, Rosenberg ES, Altfeld M, Walker BD. CD8+T lymphocyte responses target functionally important regions of Protease and Integrase in HIV-1 infected subjects. Journal of Translational Medicine. 2004; 2:15.
94.	Chien PC, Chen D, Chen PD, Tuen M, Cohen S, Migueles SA, Connors M, Rosenberg E, Malhotra U, Gonzalez C, Hioe CE. HIV-1-infected patients with envelope-specific lymphoproliferation or long-term nonprogression lack antibodies suppressing glycoprotein 120 antigen presentation. J Infect Dis. 2004 Mar 1; 189(5):852-61.
95.	Ali T, Scott N, Kallas W, Halliwell ME, Savino C, Rosenberg E, Ferraro M, Hohmann E. Detection of influenza antigen with rapid antibody-based tests after intranasal influenza vaccination (FluMist). Clin Infect Dis. 2004 Mar 1; 38(5):760-2.
96.	Quayle AJ, Fidel P, Rosenberg ES. Sex, alloimmunisation, and susceptibility to HIV infection. Lancet. 2004 Feb 14; 363(9408):503-4.
97.	Norris PJ, Moffett HF, Brander C, Allen TM, O'Sullivan KM, Cosimi LA, Kaufmann DE, Walker BD, Rosenberg ES. Fine specificity and cross-clade reactivity of HIV type 1 Gag-specific CD4+ T cells. AIDS Res Hum Retroviruses. 2004 Mar; 20(3):315-25.
98.	Hess C, Altfeld M, Thomas SY, Addo MM, Rosenberg ES, Allen TM, Draenert R, Eldrige RL, van Lunzen J, Stellbrink HJ, Walker BD, Luster AD. HIV-1 specific CD8+ T cells with an effector phenotype and control of viral replication. Lancet. 2004 Mar 13; 363(9412):863-6.
99.	Smith DE, Walker BD, Cooper DA, Rosenberg ES, Kaldor JM. Is antiretroviral treatment of primary HIV infection clinically justified on the basis of current evidence? AIDS. 2004 Mar 26; 18(5):709-18.
100.	Lichterfeld M, Yu XG, Waring MT, Mui SK, Johnston MN, Cohen D, Addo MM, Zaunders J, Alter G, Pae E, Strick D, Allen TM, Rosenberg ES, Walker BD, Altfeld M. HIV-1-specific cytotoxicity is preferentially mediated by a subset of CD8(+) T cells producing both interferon-gamma and tumor necrosis factor-alpha. Blood. 2004 Jul 15; 104(2):487-94.
101.	Kassutto S, Rosenberg ES. Primary HIV type 1 infection. Clin Infect Dis. 2004 May 15; 38(10):1447-53.
102.	Kaufmann DE, Bailey PM, Sidney J, Wagner B, Norris PJ, Johnston MN, Cosimi LA, Addo MM, Lichterfeld M, Altfeld M, Frahm N, Brander C, Sette A, Walker BD, Rosenberg ES. Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides. J Virol. 2004 May; 78(9):4463-77.
103.	Rodriguez WR, Addo MM, Rathod A, Fitzpatrick CA, Yu XG, Perkins B, Rosenberg ES, Altfeld M, Walker BD. CD8+ T lymphocyte responses target functionally important regions of Protease and Integrase in HIV-1 infected subjects. J Transl Med. 2004 May 21; 2(1):15.
104.	Allen TM, Altfeld M, Yu XG, O'Sullivan KM, Lichterfeld M, Le Gall S, John M, Mothe BR, Lee PK, Kalife ET, Cohen DE, Freedberg KA, Strick DA, Johnston MN, Sette A, Rosenberg ES, Mallal SA, Goulder PJ, Brander C, Walker BD. Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J Virol. 2004 Jul; 78(13):7069-78.
105.	Lichterfeld M, Yu XG, Cohen D, Addo MM, Malenfant J, Perkins B, Pae E, Johnston MN, Strick D, Allen TM, Rosenberg ES, Korber B, Walker BD, Altfeld M. HIV-1 Nef is preferentially recognized by CD8 T cells in primary HIV-1 infection despite a relatively high degree of genetic diversity. AIDS. 2004 Jul 2; 18(10):1383-92.
106.	Norris PJ, Moffett HF, Yang OO, Kaufmann DE, Clark MJ, Addo MM, Rosenberg ES. Beyond help: direct effector functions of human immunodeficiency virus type 1-specific CD4(+) T cells. J Virol. 2004 Aug; 78(16):8844-51.
107.	Lichterfeld M, Kaufmann DE, Yu XG, Mui SK, Addo MM, Johnston MN, Cohen D, Robbins GK, Pae E, Alter G, Wurcel A, Stone D, Rosenberg ES, Walker BD, Altfeld M. Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. J Exp Med. 2004 Sep 20; 200(6):701-12.
108.	Kaufmann DE, Lichterfeld M, Altfeld M, Addo MM, Johnston MN, Lee PK, Wagner BS, Kalife ET, Strick D, Rosenberg ES, Walker BD. Limited durability of viral control following treated acute HIV infection. PLoS Med. 2004 Nov; 1(2):e36.
109.	Adams BM, Banks HT, Davidian M, Kwon HD, Tran HT, Wynne SN, Rosenberg ES. HIV dynamics: Modeling, data analysis, and optimal treatment protocols. Journal of Computational and Applied Mathematics. 2005; 184:10-49.
110.	Allen TM, Altfeld M, Geer SC, Kalife ET, Moore C, O'Sullivan KM, Desouza I, Feeney ME, Eldridge RL, Maier EL, Kaufmann DE, Lahaie MP, Reyor L, Tanzi G, Johnston MN, Brander C. Draenert R, Rockstroh JK, Jessen H, Rosenberg ES, Mallal SA, Walker BD. Selective escape from CD8+T-cell responses represent a major driving force of human immunodeficiency virus type 1 (HIV-1)sequence diversity and reveals constraints on HIV-1 evolution. Journal of Virology. 2005; 79:13239-49.
111.	Allen TM, Yu XG, Kalife ET, Reyor LL, Lichterfeld M, John M, Cheng M, Allgaier RL, Mui S, Frahm N, Alter G, Brown NV, Johnston MN, Rosenberg ES, Mallal SA, Brander C, Walker BD, Altfeld M. De novo generation of escape variant-specific CD8+ T-cell responses following cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection. Journal of Virology. 2005; 79:12952-60.
112.	Altfeld M, Allen TM, Kalife ET, Frahm N, Addo MM, Mothe BR, Rathod A, Reyor LL, Harlow J, Yu XG, Perkins B, Robinson LK, Sidney J. Alter G, Lichterfeld M, Sette A, Rosenberg ES, Goulder PJ, Brander C, Walker BD. The majority of currently circulating human immunodeficiency virus type 1 clade B viruses fail to prime cytotoxic-lymphocyte responses against an otherwise immunodominant HLA-A2-restricted epitome: implication for vaccine design. Journal of Virology. 2005; 79:5000-5005.
113.	Frahm N, Adams S, Kiepiela P, Linde CH, Hewitt HS, Lichterfeld M, Sango K, Brown NV, Pae E, Wurcel AG, Altfeld M, Feeney ME, Allen TM, Roach T, St. John MA, Daar ES, Rosenberg ES, Korber B. Maricola F, Walker BD, Goulder PJ, Brander C. HLA-B63 presents HLA-B57/B58-restricted cytotoxic T-Lymphocyte epitopes and is associated with low human immunodeficiency virus load. Journal of Virology. 2005; 79:10218-10225.
114.	Kassutto S, Johnston MN, Rosenberg ES. Incomplete HIV-1 antibody evolution and sero-reversion in acutely infected individuals treated with early antiretroviral therapy. Clinical Infectious Diseases. 2005; 40(6):868-73.
115.	Kassutto S, Rosenberg ES. Editorial comment: Treatment of acute HIV infection-uncertainties about best practice. AIDS Reader. 2005; 15:249-51.
116.	Kavanaugh DG, Kaufmann DE, Sunderji S, Frahm N, Le Gall S, Boczkowski D, Rosenberg ES, Stone DR, Johnston MN, Wagner BS, Zaman MT, Brander C, Gilboa E, Walker BD, Bhardwaj N. Expansion of HIV-specific CD4+ and CD8+T cells by dendritic cells transfected with mRNA encoding cytoplasm-or lysosome-targeted Nef. Blood. 2005; 107(5):1963-9.
117.	Robinson JE, Elliott DH, Martin EA, Micken K, Rosenberg ES. High frequencies of antibody responses to CD4 induced epitopes in HIV infected patients started on HAART during acute infection. Hum Antibodies. 2005; 14(3-4):115-21.
118.	Seth N, Kaufmann D, Lahey T, Rosenberg ES, Wucherpfennig KW. Expansion and contraction of HIV-specific CD4 T cells with short bursts of viremia, but physical loss of the majority of these cells with sustained viral replication. Journal of Immunology. 2005; 175(10):6948-58.
119.	Xiang SH, Farzan M, SiZ, Madani N, Wang L, Rosenberg ES, Robinson J, Sodroski J. Functional mimicry of a human immunodeficiency virus type 1 coreceptor by a neutralizing monoclonal antibody. Journal of Virology. 2005; 79:6068-6077.
120.	Zaunders JJ, Munier ML, Kaufmann DE, Ip S, Grey P, Smith D, Ramacciotti T, Quan D, Finlayson R, Kaldor J, Rosenberg ES, Walker BD, Cooper DA, Kelleer AD. Early proliferation of CCR5+CD38+++antigen-specific CD4+Th 1 effector cells during primary HIV-1 infection. Blood. 2005; 106:1660-1670.
121.	Kassutto S, Johnston MN, Rosenberg ES. Incomplete HIV type 1 antibody evolution and seroreversion in acutely infected individuals treated with early antiretroviral therapy. Clin Infect Dis. 2005 Mar 15; 40(6):868-73.
122.	Altfeld M, Allen TM, Kalife ET, Frahm N, Addo MM, Mothe BR, Rathod A, Reyor LL, Harlow J, Yu XG, Perkins B, Robinson LK, Sidney J, Alter G, Lichterfeld M, Sette A, Rosenberg ES, Goulder PJ, Brander C, Walker BD. The majority of currently circulating human immunodeficiency virus type 1 clade B viruses fail to prime cytotoxic T-lymphocyte responses against an otherwise immunodominant HLA-A2-restricted epitope: implications for vaccine design. J Virol. 2005 Apr; 79(8):5000-5.
123.	Xiang SH, Farzan M, Si Z, Madani N, Wang L, Rosenberg E, Robinson J, Sodroski J. Functional mimicry of a human immunodeficiency virus type 1 coreceptor by a neutralizing monoclonal antibody. J Virol. 2005 May; 79(10):6068-77.
124.	Alter G, Teigen N, Davis BT, Addo MM, Suscovich TJ, Waring MT, Streeck H, Johnston MN, Staller KD, Zaman MT, Yu XG, Lichterfeld M, Basgoz N, Rosenberg ES, Altfeld M. Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection. Blood. 2005 Nov 15; 106(10):3366-9.
125.	Frahm N, Adams S, Kiepiela P, Linde CH, Hewitt HS, Lichterfeld M, Sango K, Brown NV, Pae E, Wurcel AG, Altfeld M, Feeney ME, Allen TM, Roach T, St John MA, Daar ES, Rosenberg E, Korber B, Marincola F, Walker BD, Goulder PJ, Brander C. HLA-B63 presents HLA-B57/B58-restricted cytotoxic T-lymphocyte epitopes and is associated with low human immunodeficiency virus load. J Virol. 2005 Aug; 79(16):10218-25.
126.	Allen TM, Yu XG, Kalife ET, Reyor LL, Lichterfeld M, John M, Cheng M, Allgaier RL, Mui S, Frahm N, Alter G, Brown NV, Johnston MN, Rosenberg ES, Mallal SA, Brander C, Walker BD, Altfeld M. De novo generation of escape variant-specific CD8+ T-cell responses following cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection. J Virol. 2005 Oct; 79(20):12952-60.
127.	Kavanagh DG, Kaufmann DE, Sunderji S, Frahm N, Le Gall S, Boczkowski D, Rosenberg ES, Stone DR, Johnston MN, Wagner BS, Zaman MT, Brander C, Gilboa E, Walker BD, Bhardwaj N. Expansion of HIV-specific CD4+ and CD8+ T cells by dendritic cells transfected with mRNA encoding cytoplasm- or lysosome-targeted Nef. Blood. 2006 Mar 1; 107(5):1963-9.
128.	Allen TM, Altfeld M, Geer SC, Kalife ET, Moore C, O'sullivan KM, Desouza I, Feeney ME, Eldridge RL, Maier EL, Kaufmann DE, Lahaie MP, Reyor L, Tanzi G, Johnston MN, Brander C, Draenert R, Rockstroh JK, Jessen H, Rosenberg ES, Mallal SA, Walker BD. Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J Virol. 2005 Nov; 79(21):13239-49.
129.	Seth N, Kaufmann D, Lahey T, Rosenberg ES, Wucherpfennig KW. Expansion and contraction of HIV-specific CD4 T cells with short bursts of viremia, but physical loss of the majority of these cells with sustained viral replication. J Immunol. 2005 Nov 15; 175(10):6948-58.
130.	Altfeld M, Kalife ET, Qi Y, Streeck H, Lichterfeld M, Johnston MN, Burgett N, Swartz ME, Yang A, Alter G, Yu XG, Meier A, Rockstroh JK, Allen TM, Jessen H, Rosenberg ES, Carrington M, Walker BD. HLA Alleles associated with delayed progression to AIDS contribute strongly to the initial CD8(+) T cell response against HIV-1. PLos Med. 2006; 3(10):e403.
131.	Barbour JD, Hecht FM, Little SJ, Markowitz M, Daar ES, Kelleher AD, Routy JP, Campbell TB, Tosenberg ES, Segal MR, Weidler J, Grant RM. Greater CD4 T-cell gains after one year of antiretroviral therapy are associated with lower HIV-1 pol replication capacity. AIDS. 2006; 20(16):2123-5.
132.	Branda JA, Lin TYD, Rosenberg ES, Halpern EF, Ferraro MJ. A rationale approach to the stool ova and parasites examination. Clinical Infectious Diseases. 2006; 42(7):972-8.
133.	Daskalakis D, Rosenberg ES. Impairment of HIV-specific immune effector cell function. Cell Death During HIV Infection. 2006; 185.
134.	Evian CI, Al-Momani A, Rosenberg ES, Sanavi F. Therapeutic management for immediate implant placement in sites with periapical deficiencies where coronal bone is present: technique and case report. Int J Oral Maxillofax Implants. 2006; 21(3):476-80.
135.	Kassutto S, Maghsoudi K, Johnston MN, Robbins GK, Burgett NC, Sax PE, Cohen D, PAE E, David B, Zachary K, Basgov N, D'agata EM, DeGruttola V, Walker BD, Rosenberg ES. Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection. Clin Infect Dis. 2006; 42(7):1024-31.
136.	Lichterfeld M, Williams KL, Mui SK, Shah SS, Mothe BR, Sette A, Kim A, Johnston MN, Burgett N, Frahm N, Cohen D. Brander C. Rosenberg ES, Walker BD, Altfeld M, Yu XG. T cell receptor cross-recognition of an HIV-1 CD8+T cell spitope presented by closely related alleles from the HLA-A3 superfamily. Int Immunol. 2006; 18(7):1179-88.
137.	Meyer-Olson D, Brady K, Bartman MT, O'Sullivan KM, Simons BC, Conrad JA, Duncan CB, Lorey S, Siddique A, Draenert Rm, Addo M, Altfeld A, Rosenberg ES, Allen T, Walker BD, Kalams SA. Fluctuations of functionally distinct CD8+T cell clonotypes demonstrate flexibility of HIV-specific TCR repertoire. Blood. 2006; (in press).
138.	Zaunders JJ, Ip S, Munier ML, Kaufmann DE, Suzuki K, Brereton C, Sasson SC, Seddiki N, Koelsch K, Landay A, Grey P, Finlayson R, Kaldor J, Rosenberg ES, Walker BD, Fazekas de St. Groth B, Cooper DA, Kelleher AD,. Infection of CD127+(interleukin-7 receptor+)CD4+ cells and overexpression of CTLA-4 are linked to loss of antigen-specific CD4 T cells during primary human immunodeficiency virus type 1 infection. J Virol. 2006; 80(20):10162-72.
139.	Branda JA, Lin TY, Rosenberg ES, Halpern EF, Ferraro MJ. A rational approach to the stool ova and parasite examination. Clin Infect Dis. 2006 Apr 1; 42(7):972-8.
140.	Kassutto S, Maghsoudi K, Johnston MN, Robbins GK, Burgett NC, Sax PE, Cohen D, Pae E, Davis B, Zachary K, Basgoz N, D'agata EM, DeGruttola V, Walker BD, Rosenberg ES. Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection. Clin Infect Dis. 2006 Apr 1; 42(7):1024-31.
141.	Lichterfeld M, Williams KL, Mui SK, Shah SS, Mothe BR, Sette A, Kim A, Johnston MN, Burgett N, Frahm N, Cohen D, Brander C, Rosenberg ES, Walker BD, Altfeld M, Yu XG. T cell receptor cross-recognition of an HIV-1 CD8+ T cell epitope presented by closely related alleles from the HLA-A3 superfamily. Int Immunol. 2006 Jul; 18(7):1179-88.
142.	Altfeld M, Kalife ET, Qi Y, Streeck H, Lichterfeld M, Johnston MN, Burgett N, Swartz ME, Yang A, Alter G, Yu XG, Meier A, Rockstroh JK, Allen TM, Jessen H, Rosenberg ES, Carrington M, Walker BD. HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8(+) T Cell Response against HIV-1. PLoS Med. 2006 Oct; 3(10):e403.
143.	Yu XG, Lichterfeld M, Chetty S, Williams KL, Mui SK, Miura T, Frahm N, Feeney ME, Tang Y, Pereyra F, Labute MX, Pfafferott K, Leslie A, Crawford H, Allgaier R, Hildebrand W, Kaslow R, Brander C, Allen TM, Rosenberg ES, Kiepiela P, Vajpayee M, Goepfert PA, Altfeld M, Goulder PJ, Walker BD. Mutually exclusive T-cell receptor induction and differential susceptibility to human immunodeficiency virus type 1 mutational escape associated with a two-amino-acid difference between HLA class I subtypes. J Virol. 2007 Feb; 81(4):1619-31.
144.	Adams BM, Banks HT, Davidian M. Rosenberg ES. Estimation and prediction with HIV-treatment interruption data. Bull Math Biol. 2007; 2:563-84.
145.	Lichterfeld M, Yu XG, Mui SK, Williams KL, Trocha A, Brockman MA, Allgaier RL, Waring MT, Koibuchi T, Johnston MN, Cohen D, Allen TM, Rosenberg ES, Walker BD, Altfeld M. Selective depletion of high-avidity human immunodeficiency virus type 1 (HIV-1)-specific CD8+T cells after early HIV-1 infection. J Virol. 2007; 81(8):4199-214.
146.	Lichterfeld M, Yu XG, Mui SK, Williams KL, Trocha A, Brockman MA, Allgaier RL, Waring MT, Koibuchi T, Johnston MN, Cohen D, Allen TM, Rosenberg ES, Walker BD, Altfeld M. Selective depletionof high avidity human immunodeficiency virus type 1 (HIV-1)-specific CD8+T cells after early HIV-1 infection. Journal of Virology. 2007; 81(8):4199-214.
147.	Rosenberg ES, Davidian M, Banks HT. Using mathematical modeling and control to develop structured treatment interruption strategies for HIV infection. Drug Alcohol Depend. 2007; 88(2):S41-51.
148.	Yu XG, Lichterfeld M, Chetty S, Williams KL, Mui SK, Miura T, Frahm N, Feeney ME, Tang Y, Pereyra F, Labuta MX, Pfafferott K, Leslie A, Crawford H, Allgaier R, Hildebrand W, Kaslow R, Brander C, Allen TM, Rosenberg ES, Kiepiela P, Vajpayee M, Goepfert PA, Altfeld M, Goulder PJ, Walker BD. Mutually exclusive T-cell receptor induction and differential susceptibility to human immunodeficiency virus type 1 mutational escape associated with a two-amino-acid difference between HLA class I subtypes. J Virol. 2007; 81(4):1619-31.
149.	Rosenberg ES, Davidian M, Banks HT. Using mathematical modeling and control to develop structured treatment interruption strategies for HIV infection. Drug Alcohol Depend. 2007 May; 88 Suppl 2:S41-51.
150.	Lichterfeld M, Yu XG, Mui SK, Williams KL, Trocha A, Brockman MA, Allgaier RL, Waring MT, Koibuchi T, Johnston MN, Cohen D, Allen TM, Rosenberg ES, Walker BD, Altfeld M. Selective depletion of high-avidity human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T cells after early HIV-1 infection. J Virol. 2007 Apr; 81(8):4199-214.
151.	Addo MM, Draenert R, Rathod A, Verrill CL, Davis BT, Gandhi RT, Robbins GK, Basgoz NO, Stone DR, Cohen DE, Johnston MN, Flynn T, Wurcel AG, Rosenberg ES, Altfeld M, Walker BD. Fully differentiated HIV-1 specific CD8+ T effector cells are more frequently detectable in controlled than in progressive HIV-1 infection. PLoS ONE. 2007; 2(3):e321.
152.	Addo MM, Draenert R, Rathod A,Verrill CL, Davis BT, Gandhi RT, Robbins GK, Basgov NO, Stone DR, Cohen DE, Johnston MN, Flynn T, Wurcel AG, Rosenberg ES, Altfeld M, Walker BD. Fully differentiated HIV-1 specific CD8+T effector cells are more frequently detectable in controlled than in progressive HIV-1 infectionl. PloS ONE. 2007; 2(e):321.
153.	Alter G, Teigen N, Ahern R, Streeck H, Meier A, Rosenberg ES, Altfeld M. Evolution of innate and adaptive effector cell functions during acute HIV-1 infection. J Infect Dis. 2007 May 15; 195(10):1452-60.
154.	Streeck H, Lichterfeld M, Alter G, Meier A, Teigen N, Yassine-Diab B, Sidhu HK, Little S, Kelleher A, Routy JP, Rosenberg ES, Sekaly RP, Walker BD, Altfeld M. Recognition of a defined region within p24 gag by CD8+ T cells during primary human immunodeficiency virus type 1 infection in individuals expressing protective HLA class I alleles. J Virol. 2007 Jul; 81(14):7725-31.
155.	Streeck H, Lichterfeld M, Alter G, Meier A, Teigen N, Yassine-Diab B, Sidhu HK, Little S, Kelleher A, Routy JP, Rosenberg ES, Sekaly RP, Walker BD, Altfeld M. Recognition of a defined region within p24 Gag by CD8+T cells during primary HIV-1 infection in individuals expressing protective HLA class I alleles. J Virol. 2007; in press.
156.	Alter G, Teigen N, Ahern R, Streeck H, Meier A, Rosenberg, ES, Altfeld M. Evolution of innate and adaptive effector cell functions during acute HIV-1 infection. J. Infect Dis. 2007; 195(10):1452-60.
157.	Kaufmann DE, Kavanagh DG, Pereyra F, Zaunders JJ, Mackey EW, Miura T, Palmer S, Brockman M, Rathod A, Piechocka-Trocha A, Baker B, Zhu B, Le Gall S, Waring MT, Ahern R, Moss K, Kelleher AD, Coffin JM, Freeman GJ, Rosenberg ES, Walker BD. Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol. 2007 Nov; 8(11):1246-54.
158.	Rychert J, Saindon S, Placek S, Daskalakis D, Rosenberg E. Sequence variation occurs in CD4 epitopes during early HIV infection. J Acquir Immune Defic Syndr. 2007 Nov 1; 46(3):261-7.
159.	Lichterfeld M, Kavanagh DG, Williams KL, Moza B, Mui SK, Miura T, Sivamurthy R, Allgaier R, Pereyra F, Trocha A, Feeney M, Gandhi RT, Rosenberg ES, Altfeld M, Allen TM, Allen R, Walker BD, Sundberg EJ, Yu XG. A viral CTL escape mutation leading to immunoglobulin-like transcript 4-mediated functional inhibition of myelomonocytic cells. J Exp Med. 2007 Nov 26; 204(12):2813-24.
160.	Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, Rathod A, Baker B, Trocha A, Rosenberg R, Mackey E, Ueda P, Lu Z, Cohen D, Wrin T, Petropoulos CJ, Rosenberg ES, Walker BD. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis. 2008 Feb 15; 197(4):563-71.
161.	Streeck H, Brumme ZL, Anastario M, Cohen KW, Jolin JS, Meier A, Brumme CJ, Rosenberg ES, Alter G, Allen TM, Walker BD, Altfeld M. Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells. PLoS Med. 2008 May 6; 5(5):e100.
162.	Streeck H, Li B, Poon AF, Schneidewind A, Gladden AD, Power KA, Daskalakis D, Bazner S, Zuniga R, Brander C, Rosenberg ES, Frost SD, Altfeld M, Allen TM. Immune-driven recombination and loss of control after HIV superinfection. J Exp Med. 2008 Aug 4; 205(8):1789-96.

 

Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.

Rosenberg's...